Collegium Pharmaceutical (COLL) EBT (2014 - 2026)

Collegium Pharmaceutical has reported EBT for 13 years, with the latest figure at -$13.5 million in Q2 2026.

• On a quarterly basis, EBT fell 179.48% year-over-year to -$13.5 million in Q2 2026; TTM through Jun 2026 was $77.7 million, a 46.58% increase from a year earlier, with the FY2025 full-year figure at $92.6 million, down 6.04% from the prior year.
• EBT was -$13.5 million for Q2 2026 at Collegium Pharmaceutical, down from $18.7 million in the prior quarter.
• The five-year high for EBT was $46.7 million in Q4 2023, with the low at -$17.6 million in Q1 2023.
• Average EBT over 5 years is $13.5 million, with a median of $17.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: EBT sank 202.38% in 2022, then surged 1909.99% in 2023.
• Over 5 years, EBT stood at -$7.8 million in 2022, then jumped by 699.54% to $46.7 million in 2023, then sank by 63.03% to $17.3 million in 2024, then surged by 68.14% to $29.0 million in 2025, then plunged by 146.6% to -$13.5 million in 2026.
• The last three EBT figures came in at -$13.5 million (Q2 2026), $18.7 million (Q1 2026), and $29.0 million (Q4 2025), per Business Quant data.